SCHEMBL178707

SCHEMBL178707

COc1ccc(-c2cc(C)c3[nH]c4nc(OC)ccc4c3n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.69
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
EGFR P00533 1/20 0.40
KDR P35968 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
TNKS O95271 1/20 0.39
PARP1 P09874 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
LIG1 P18858 1/20 0.39
ACP1 P24666 1/20 0.39
ALK Q9UM73 1/20 0.39
DYRK1A Q13627 2/20 0.38
ACACA Q13085 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144466 0.83 JAK2 (0.82) JAK2KDM4ENPC1RAB9AALDH1A1
SCHEMBL143932 0.83 JAK2 (0.82) JAK2KDM4ENPC1RAB9AALDH1A1
SCHEMBL142279 0.82 JAK2 (1.00) JAK2KDM4EMEN1NPC1RAB9A
SCHEMBL178818 0.81 JAK2 (0.65) JAK2KDM4EMEN1NPC1RAB9A
SCHEMBL178819 0.73 JAK2 (0.47) JAK2KDM4EMEN1NPC1RAB9A
SCHEMBL12112639 0.68 MAPT (0.43) JAK2KDM4EMEN1NPC1RAB9A
SCHEMBL141522 0.66 JAK2 (0.80) JAK2KDM4ENPC1RAB9ADYRK1A
SCHEMBL143862 0.65 JAK2 (1.00) JAK2KDM4EDYRK1AALDH1A1LMNA
SCHEMBL142655 0.64 JAK2 (0.78) JAK2KDM4ENPC1RAB9ADYRK1A
SCHEMBL9704213 0.64 EGFR (0.60) KDM4EMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885KDM4E 928/4885MEN1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.